Dendritic cell vaccines
provide another form of therapy for conditions that cannot be addressed with chemotherapy or radiation, such as metastatic renal cancer or malignant melanoma.
Palucka is working to develop a dendritic cell vaccine
against triple-negative tumors based on long peptides.
In the first quarter of 2013, we anticipate the initiation of an investigator-sponsored Phase I trial of ICT-121, a dendritic cell vaccine
targeting CD133, in patients with recurrent glioblastoma.
We are planning to initiate a 20-patient, investigator-sponsored Phase I trial of ICT-121, a dendritic cell vaccine
targeting CD133, in patients with recurrent glioblastoma, also before the end of 2012.
These data demonstrate that our dendritic cell vaccine
, ICT-107, which was designed to target both cancer cells and cancer stem cells, has the potential to significantly delay disease recurrence, and thus increase survival in GBM," said Manish Singh, Ph.
Steve's broad experience in immunology drug discovery and development, as well as his regulatory knowledge and worldwide reputation as an immunogenicity thought-leader will be valuable assets to ImmunoCellular both in advancing this new stem cell platform and potentially enhancing our dendritic cell vaccine
Rosenthal will introduce the LEAPS dendritic cell vaccine
approach as a potentially new personalized immunotherapy for chronic viral infections and tumors at the Cancer Vaccine Meeting in Cambridge, Mass.
Study Supports Potential for Off-the-Shelf Dendritic Cell Vaccine
The company's lead immunotherapy programs include a CTA targeted dendritic cell vaccine
in Phase 1/2 development for multiple tumor types and an NIH supported CTA targeted oral cancer vaccine in preclinical development for ovarian and other cancers.
AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic approach to dendritic cell vaccines
In order to make dendritic cell vaccines
some of the patient's dendritic cells are extracted and immune cell stimulants are used to reproduce large amounts of dendritic cells in the lab.
The company is focusing on development of its dendritic cell vaccines
If the melanoma trial is successful, ML will be seeking partners interested in using the technology to develop dendritic cell vaccines
for a range of life threatening diseases.
Tetanus toxoid and CCL3 improve dendritic cell vaccines
in mice and glioblastoma patients.
Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines
, T-cell therapies and cancer vaccines.